Skip to search formSkip to main contentSkip to account menu

Interferon beta-1a 0.03 MG Injection [Avonex]

Known as: Avonex 0.03 MG Injection, AVONEX KIT, interferon beta-1a 30 ug in 1 mL INTRAMUSCULAR INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AVONEX] 
National Institutes of Health

Related topics

Related topics

10 relations
Acetic AcidArginine hydrochlorideAvonexInjection

Broader (1)

Interferon beta-1a 0.03 MG Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
MxA protein induction in MS patients treated with intramuscular IFNβ-1a
MxA protein production in peripheral blood leukocytes is a valuable marker to evaluate biologic effects of interferon-beta (IFN… 
Review
2004
Review
2004
Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications
Interferon beta (IFNβ) and glatiramer acetate are the standard of care for the treatment of patients with relapsing MS. Three… 
Review
2004
Review
2004
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
Protein- and peptide-based disease-modifying agents for multiple sclerosis (MS), including interferon beta (IFNβ) and glatiramer… 
Review
2004
Review
2004
Is multiple sclerosis a disease that requires frequent beta interferon dosing?
Abstract.The three currently available beta interferon products for the treatment of patients with relapsing-remitting multiple… 
2002
2002
Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial
BackgroundInterferon &bgr; (IFN&bgr;) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects… 
Review
2002
Review
2002
Providing pharmaceutical care to the multiple sclerosis patient.
OBJECTIVE To review the pathophysiology, symptoms, and treatment of multiple sclerosis (MS). DATA SOURCES Recently published… 
2002
2002
Interferon β1a (Avonex®) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability
Objective To compare clinical responses to once-weekly intramuscular interferon-β-1 a [IFNβ-1 a, Avonex®, Biogen] in multiple… 
2000
2000
Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics
1998
1998
Recent advances in preclinical drug development in multiple sclerosis
Recently approved therapies for treatment of relapsing-remitting multiple sclerosis (MS) include interferon β1b (IFNβ1b… 
1998
1998
Treatment of Multiple Sclerosis with the Interferon-βs
Several inteferons (IFNs) have recently been introduced for the treatment of multiple sclerosis (MS). These are IFNβ-1b… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)